RE: Lots of positives in that27 Jan 2026 15:29
"Administrative expenses widened by 30% to GBP660,569 from GBP506,353. Meanwhile, Nuformix posted no impairment of goodwill for financial 2025, compared to GBP3.6 million in financial 2024. Looking ahead, the company said the main priority for directors is to focus on the firm's NXP002 programme and specifically to find a business development partner."
So, the Co is spending more, gearing up for the development phase IMO and getting ready for a partner - why do that, if too much uncertainty with the outcome in the USA? it's been more than 10 weeks since the FDA query, does anyone think that - had the FDA been unsatisfied with the response - it would not have rejected the application by now? All IMO. Co keeps referring to "partners", can we reasonably assume that these (more than 1) potential partners are just waiting for the ODD designation before signing an agreement with NFX? I mean, why commit now and not wait until the ODD? It doesn't mean though that there are no interested parties; but the number crunching can only begin once the FDA responds, right?